Royalty Report: Medical, Diagnostic, Drugs – Collection: 5413

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Medical
  • Diagnostic
  • Drugs
  • Delivery
  • Dental
  • Pharmaceuticals
  • Device
  • Supply

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5413

License Grant
The University hereby grants an exclusive right and license to Patented Ultrasound Enhancement of Transdermal Drug Delivery and Electric Field And Ultrasound For Transdermal Drug Delivery and Enhanced Antimicrobial Activity By Ultrasound for Dental Decay and Periodontal Disease Prevention and Treatment.
License Property
Patent No. 4,767,402, Issued August 30, 1988 “Ultrasound Enhancement of Transdermal Drug Delivery”

Patent No. 4,948,587, August 14, 1990 “Ultrasound Enhancement of Transbuccal Drug Delivery”

Patent No. 4,780,212, Issued October 25, 1988 “Ultrasound Enhancement of Membrane Permeability”

Patent No. 4,948,587, August 14, 1990 “Ultrasound Enhancement of Transbuccal Drug Delivery”

U.S.S.N. 08/507,060, Filed July 25, 1995 “Transdermal Protein Delivery Using Low-Frequency Sonophoresis”

U.S.S.N. 08/511,583, Filed August 4, 1995

U.S.S.N. 08/545,236, Filed October 19, 1995 “Transdermal Protein Delivery or Measurement Using Low-Frequency Sonophoresis”

IPSCIO Record ID: 5729

License Grant
LICENSEE hereby grants back to LICENSOR the co-exclusive rights under the license granted to LICENSEE.

LICENSEE is granted an exclusive worldwide license to certain patent rights and know how relating to the determination of glucose concentration in body fluid which glucose is obtained using ultrasonic techniques.

LICENSOR will have worldwide coexclusive rights to develop and market LICENSOR's continuous transdermal glucose monitoring system using the SonoPrep ultrasonic skin permeation technology for the hospital intensive care unit (ICU) market.

License Property
Licensor Patent Rights

1

US 6,234,990 B2

US 6,234,990 B1

WO 9800194 A2

EP 0925088 A2

2

WO 0170330 A2

EP 1225831 A2

3

U.S. 6,190,315 B1

WO 99348578 A1

EP 1045714 A1

4

WO 0035357 A1

EP 1139886 A1

5

WO 0035351 A

Field of Use
Field of Use shall mean the area of determination of glucose concentration in body fluid which glucose is obtained using ultrasonic techniques.

IPSCIO Record ID: 25894

License Grant
Licensor hereby grants to Licensee an exclusive worldwide right and license under the Patent Rights and Know-How in the Field of Use, with the right to grant sublicenses, to make, have made, use, import, and sell any Licensed Products and/or Processes during the term hereof.   Licensors intellectual property relates to continuous transdermal glucose monitoring system utilizing ultrasonic techniques.
License Property
It has completed the first prototypes of its continuous glucose monitor using proprietary ultrasonic skin permeation technology for the hospital intensive care unit (ICU), and expects to begin human clinical studies in early 2006.

Licensor Patent Rights

1

US 6,234,990 B2

US 6,234,990 B1

WO 9800194 A2

EP 0925088 A2

2

WO 0170330 A2

EP 1225831 A2

3

U.S. 6,190,315 B1

WO 99348578 A1

EP 1045714 A1

4

WO 0035357 A1

EP 1139886 A1

5

WO 0035351 A

Field of Use
Field of Use shall mean the area of determination of glucose concentration in body fluid which glucose is obtained using ultrasonic techniques.

IPSCIO Record ID: 2759

License Grant
The Licensee, a spin-off of the Licensor purchased assets of iontophoresis drug delivery products and related research and development program, as well as related patents, patent applications and other intellectual property.
License Property
Iontophoresis is an active transdermal drug delivery technology.

The Licensee has developed and produced the first FDA – approved electronically controlled transdermal drug delivery system that transports drugs through the skin comfortably, without needles.  Our active transdermal drug delivery technology is based on a process known as electrotransport, or more specifically iontophoresis, a process that transports drugs, including peptides, through the skin by applying a low-level electrical current. Our active patch patented technology works by applying a charge to the drug-holding reservoir of the patch. This process differs significantly from passive transdermal drug delivery which relies on the slow, steady diffusion of drugs through the skin. A significantly greater number of drugs can be delivered through active transdermal delivery than is possible with passive transdermal delivery. Based on our analysis thus far, we estimate that there are currently over 220 FDA-approved drugs that may be delivered through our active transdermal delivery platform.

Field of Use
The Licensee is required to pay the Licensor a royalty in respect of sales of each iontophoresis product stemming from intellectual property received from the Licensor.

IPSCIO Record ID: 6066

License Grant
The Licensee exclusively licensed a portfolio of seven patents from the University for diagnostic products used in the dental field.
License Property
Optical Coherence Tomography (OCT) is generally regarded as the 6th Imaging Modality and is a new, light-based system with characteristics that make it ideally suited to bio-medical diagnostic imaging applications.  OCT represents a major advancement in imaging in dentistry due its ability to provide detailed characterization of the dental microstructures, enabling the dentist to make earlier and more accurate diagnosis of oral disease including decay and periodontal disease.  The early detection of tooth decay facilitates the dentist to employ non- or minimally invasive techniques to treat or even reverse decay and periodontal disease.  Less invasive treatment enhances the patient experience and results in a higher level of professional service and patient care. The proprietary OCT Dental Imaging System(TM) will be used by dentists to obtain a real-time chairside evaluation of the oral tissues to aid in the early detction of decay, periodontal disease and microstructural deficiencies.

In general, Optical Coherence Tomography, or ‘OCT’, is a technique for obtaining sub-surface images of translucent or opaque materials at a resolution equivalent to a low-power microscope. It is effectively ‘optical ultrasound’, imaging reflections from within tissue to provide cross-sectional images.

Patent No.
5,570,182; 6,179,611; 6,385,358; 6,419,484; 6,451,009; 6,466,713, 6,522,407

Field of Use
The rights granted apply to the dental field.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.